**COE Learning Network:** Pre and Postnatal Care for Individuals with Opioid Use Disorder (OUD)

**Presenters:** Cambria King and Corey Davis

**Date and Time: 6/28/23** - 12 pm to 1:15 pm

**Location:**Virtual Training (on Zoom)

**Host:**University of Pittsburgh, School of Pharmacy, Program and Evaluation Unit (PERU)

**Target Audience:**Centers of Excellence Leadership and Staff

**Training Objectives:**

* Understand the gold standard recommendations for treatment of opiate use disorder (OUD) in the perinatal period
* Understand the effects of MOUD on the mother-baby dyad throughout the perinatal period
* Interact with patients and their support persons in a way that is non-stigmatizing and empowering of their recovery
* Recognize and practice principles of harm reduction, including universal distribution of Narcan with the understanding of how to administer it when necessary

**Agenda:**

1. Welcome, introductions, training objectives
2. Overview of opioid use disorder (OUD)
3. Describing the role of the provider
4. Person first language
5. Medication for OUD (MOUD)
	1. Effectiveness of MOUD
	2. MOUD in Pregnancy
6. Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS)
	1. Tools for addressing NAS and NOW
7. Parental Partnership Unit (PPU)
	1. PPU data
8. Recommendations for discharge
9. Harm reduction
	1. Naloxone
10. Discussion
11. Questions

**Questions:**

1. Some barriers to seeking care include:
	1. Lack of a support system
	2. Lack of childcare
	3. Food insecurity
	4. Unstable housing
	5. **All the above**
2. **True** or False: Both methadone and buprenorphine decrease cravings and physical withdrawal symptoms.
3. True or **False**: Neonatal Opioid Withdrawal Syndrome (NOWS) occurs only if the person giving birth used illegal opioids.
4. Some discharge recommendations for infants with opioid exposure include:
	1. Drug testing caretakers daily
	2. Referring all families to child welfare services
	3. **Early intervention service referral**
	4. None of the above
5. Naloxone works in the body for:
	1. 24 hours
	2. **30 to 90 minutes**
	3. 6 months
	4. None of the above

**References:**

American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy. https://www.acog.org/clinical/clinical-guidance/committeeopinion/articles/2017/08/opioid-use-and-opioid-use-disorder-in- pregnancy

Anbalagan S & Mendez M. (2021). Neonatal abstinence syndrome. https://www.ncbi.nlm.nih.gov/books/NBK551498/

Connery, H. (2015). Medication-assisted treatment of opioid use disorder: Review of evidence and future directions. Harvard Review of Psychiatry. 23(2). https://doi:10.1097/HRP.0000000000000000075

Goetz, E. (n.d.). Assessment of Neonatal Abstinence Syndrome: Standard Scoring of Infants using the Finnegan Scoring Tool. PowerPoint. https://www.ihs.gov/sites/opioids/themes/responsive2017/display\_objects/documents/NASNursingStaffEducation.pdf#:~:text=Also%20known%20as%20the%20Finnegan%20Scoring%20System.%20This,24%20hours%2C%20every%204%20hours%20after%2048%20hours.

Grossman, M., Minear, S., Whalen, B. & Wachman, E. (2017). Eating, sleeping, consoling (ESC) neonatal abstinence syndrome care tool: Instructional manual. Boston Medical Center Corporation.

Miller, W. R., Forcehimes, A., & Zweben, A. (2019). Treating Addiction: A Guide for Professionals Second Edition. New York: Guilford Press.

National Institute on Drug Abuse. (2021). *Words matter - Terms to use and avoid when talking about addiction.* https://nida.nih.gov/nidamed-medical-health-professionals/healthprofessions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction

National Institute of Mental Health. (2021). *Substance use and co-occurring mental disorders.* https://www.nimh.nih.gov/health/topics/substance-use-and-mental-health.

Payte, J. T. (2002). Opioid agonist treatment of addiction. Slide presentation at ASAM Review Course in Addiction Medicine.

Patrick, S., Barfield, W., Poindexter, B., Cummings, J., Hand, I., Adams-Chapman, I., Aucott, S., Puopolo, K., Goldsmith, K., Kaufman, D., Martin, C., Mowitz, M., Gonzalez, L., Camenga, D., Quigley, J.. Ryan, S., & Walker-Harding, L. (2020). Neonatal Opioid Withdrawal Syndrome. *American Academy of Pediatrics.* 146 (5). e2020029074. 10.1542/peds.2020-029074

Weller, A. E., Crist, R. C., Reiner, B. C., Doyle, G. A., & Berrettini, W. H. (2021). Neonatal opioid withdrawal syndrome (NOWS): A transgenerational echo of the opioid crisis. *Cold Spring Harbor Perspectives in Medicine.* 11(3). https://doi.org/10.1101/cshperspect.a039669